Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and ...

The Global Point-of-Care Molecular Diagnostics Market is projected to grow at a CAGR of 10.2% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals ...

The Rising Wave of Esoteric Testing The Esoteric Testing Market represents a specialized segment of diagnostic laboratory services that focuses on rare and complex tests not routinely performed in ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research ...

According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is ...

MedGenome, a leading global genomics-driven diagnostics and research services company, has announced a majority investment in Gujarat-headquartered pathology laboratory chain, Green Cross Genetics Lab ...

Breast cancer detection has evolved from microscopes to molecular precision to offer diagnostic insights: Expert: Shardul Nautiyal, Mumbai Saturday, November 1, 2025, 08:00 Hrs [I ...

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

Around 25 million Americans have a rare genetic disease, and many of them struggle with not only a lack of effective ...

A new deep learning framework can accurately classify four molecular subgroups of medulloblastoma and predict critical ...

According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .